Reach the investors backing rounds like this
Backed by Eli Lilly & Company, Adage +4 more · verified emails and LinkedIn on Datapile
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Stocktwits
Absci Corporation is a biotechnology company developing ABS-201, a drug for pattern hair loss and endometriosis. The company announced positive early clinical trial data for ABS-201, showing it was well-tolerated and had a long-lasting presence in the body. This news coincided with a $100 million stock offering to fund further development.
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise Stocktwits
| Oct 08, 2026 | Natron Energy | $10.2M | — | United States |
| Oct 08, 2026 | Hone | $60.0M | Seed | United States |
| Oct 08, 2026 | Arena | $200.0M | Series B | United States |
| Oct 08, 2026 | Quaise Energy | $25.0M | Grant | United States |
You just read who funded Absci Corporation. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.